Human Genome partners with FivePrime
FivePrime Therapeutics will get an upfront license payment of $50 million and will be eligible to receive up to $445 million in milestone payments, along with double-digit royalties on net sales.
FivePrime will retain minority co-promotion rights in the U.S. and full development and commercialization rights in the rest of world, including Asia, the companies said in a statement.
The drug, FP-1039, targets multiple fibroblast growth factor ligands. It is currently in mid-stage trials for a form of endometrial cancer.